BRAIN METASTASES:
SURGERY VS GAMMA KNIFE VS WBRT
Three treatment modalities — one decision that changes outcomes and quality of life. Understanding when each approach is preferred (and when combinations are used) is the most important knowledge a brain metastasis patient can have.
analyticsAt a Glance
- check_circleGamma Knife (SRS) is now first-line for 1–4 brain metastases in most guidelines — replacing WBRT
- check_circleSurgery preferred when a single large symptomatic lesion needs decompression or tissue diagnosis
- check_circleWBRT used for multiple small metastases (5+) or leptomeningeal disease — with significant cognitive cost
- check_circleCancerFax connects patients with Gamma Knife centres and surgical neuro-oncology teams in China and India
Brain Metastases — Understanding the Treatment Landscape
Brain metastases — cancer cells that have spread from a primary tumour elsewhere in the body to the brain — are the most common intracranial tumours in adults. Treatment aims to control lesions, relieve symptoms, and preserve neurological function and quality of life.
“The question is no longer just 'can we treat brain metastases?' — it is 'which treatment preserves the most brain function while achieving the best local control?'”
Who Gets Brain Metastases?
Lung cancer (40–50%), breast cancer (15–25%), melanoma (10–15%), colorectal cancer, and renal cell carcinoma are the most common primary cancers to metastasise to the brain. They are more common than primary brain tumours.
How Are They Found?
MRI brain with gadolinium contrast is the gold standard — it detects lesions as small as 2–3 mm. CT is used in emergency settings. Staging MRI should be performed in all patients with high-risk primary cancers at diagnosis.
Surgery vs Gamma Knife vs WBRT — Quick Comparison
A structured comparison of the three main treatment modalities across the dimensions that matter most for clinical decision-making.
| Factor | Surgery | Gamma Knife / SRS | Whole Brain RT (WBRT) |
|---|---|---|---|
| Best for | Single large lesion (>3–4 cm), symptomatic, needs decompression, or tissue diagnosis required | 1–4 lesions, each <3 cm, good performance status | 5+ lesions, leptomeningeal disease, poor PS, palliative intent |
| Local control | ~80–90% at 1 year for single resected lesion | 80–90% at 1 year for SRS-treated lesions | 60–80% short-term, lower long-term; higher new lesion rate |
| Cognitive impact | Risk from surgery itself; low if awake approach used | Minimal — spares the rest of the brain | Significant — neurocognitive decline in 50–90% at 4 months |
| Treatment sessions | Single operation (anaesthesia required) | Single session or 3–5 fractions (no anaesthesia) | 10–15 daily fractions over 2–3 weeks |
| Evidence base | Multiple RCTs: surgery + RT vs RT alone | EORTC 22952, Alliance N0574, JROSG99, multiple RCTs | Long-established; QUARTZ trial shows limited benefit in poor PS NSCLC |
| Typical cost (India) | ₹2–4 lakh (INR) | ₹1.5–3 lakh (INR) | ₹80,000–1.5 lakh (INR) |
How Oncologists Choose Between Modalities
The treatment decision follows a structured algorithm based on lesion characteristics, patient performance status, and primary cancer status. These are the key decision points.
- 1
Step 1 — How Many Lesions?
1–4 lesions: SRS/Gamma Knife preferred in most guidelines. 5+ lesions: WBRT or SRS-to-all-sites at specialist centres. Leptomeningeal disease: WBRT or intrathecal therapy.
- 2
Step 2 — Lesion Size?
Lesions >3–4 cm: surgery strongly preferred — SRS alone has lower local control for large lesions and risks radiation necrosis. Lesions <3 cm: SRS achieves comparable control to surgery without craniotomy.
- 3
Step 3 — Symptomatic / Needs Diagnosis?
Symptomatic (significant oedema, herniation risk, neurological deficit): surgery for decompression. Unknown primary or tissue needed to guide systemic therapy: surgery provides tissue. Incidental/asymptomatic: SRS.
- 4
Step 4 — Primary Cancer Status?
Active systemic disease responding to systemic therapy: focus on local control with SRS, continue systemic therapy. Refractory systemic disease with poor prognosis: WBRT may be appropriate for palliative intent.
- 5
Step 5 — Add WBRT After SRS?
WBRT after SRS improves intracranial control but significantly worsens neurocognitive function. Most current guidelines recommend SRS alone with close MRI surveillance, reserving WBRT for salvage.
SRS/Gamma Knife vs WBRT — The Evidence-Based Choice
The shift from WBRT to SRS as the preferred modality for limited brain metastases has been driven by multiple randomised trials demonstrating equivalent survival with significantly better neurocognitive outcomes.
SRS / Gamma Knife (Preferred for 1–4 Lesions)
- Equivalent or better local controlAlliance N0574 showed no OS difference vs WBRT + SRS — confirming SRS alone does not compromise survival.
- Significantly better neurocognitionN0574 showed 63.5% neurocognitive failure rate at 3 months with SRS+WBRT vs 91.7% with SRS alone — a striking protection of cognitive function.
- Outpatient, single sessionNo anaesthesia, no craniotomy, no hospital admission — Gamma Knife is treated as an outpatient procedure in most centres.
WBRT (Reserved for Specific Indications)
- Still preferred for 5+ small lesionsWhen the total number of lesions is high, WBRT may achieve more durable intracranial control than SRS to all sites — though this is evolving.
- Required for leptomeningeal diseaseLeptomeningeal carcinomatosis involves diffuse CNS disease — not discrete lesions — requiring whole-brain or craniospinal RT.
- Palliative option for poor PS patientsThe QUARTZ trial showed WBRT provides modest quality-adjusted life year benefit in NSCLC patients with poor performance status who are not candidates for SRS.
Local Control and Survival: Key Trial Data
Landmark trials comparing SRS versus WBRT provide the evidence base for modern brain metastasis treatment guidelines.
Alliance N0574 — SRS Alone vs SRS + WBRT (1–3 Metastases)
Source: Brown et al, JAMA 2016. Neurocognitive failure = decline from baseline at 3 months.
- Neurocognitive failure — SRS alone63.5%
- Neurocognitive failure — SRS + WBRT91.7%
- Median OS — SRS alone10.7 mo
- Median OS — SRS + WBRT7.4 mo
EORTC 22952 — SRS / Surgery vs + WBRT
Source: Kocher et al, J Clin Oncol 2011. WBRT added after local treatment.
- 2-yr intracranial control — with WBRT73%
- 2-yr intracranial control — without WBRT27%
- OS — no difference between armsp=NS
Frequently Asked Questions
Common questions from patients and families deciding between brain metastasis treatment options.
I have 3 brain metastases — should I have surgery, Gamma Knife, or both?
For 3 lesions, Gamma Knife (SRS) is typically the preferred approach unless any individual lesion is >3–4 cm, causing significant oedema or neurological symptoms. If one lesion is large and symptomatic, surgery to that lesion plus SRS to the remaining smaller lesions is a common combined approach.
Will whole brain radiation damage my memory?
Yes — neurocognitive decline is the primary limitation of WBRT. Studies show 50–90% of patients experience measurable cognitive decline at 4 months. Hippocampal-avoidance WBRT (HA-WBRT) with memantine reduces this risk and is now standard where available. SRS completely avoids this risk by treating only the lesions.
My oncologist recommends WBRT for 8 brain metastases — is SRS not possible for that many?
SRS to multiple lesions (5–10) is performed at specialist centres and is increasingly supported by data — the Japanese JLGK0901 study showed similar OS for SRS to 5–10 metastases vs 2–4. However, this requires a high-volume centre with appropriate planning software. CancerFax can identify centres in China and India performing multi-lesion SRS.
How soon after starting systemic therapy should brain metastases be treated?
This depends on the primary cancer type. For HER2+ breast cancer or EGFR-mutant NSCLC, systemic therapy with CNS-penetrant drugs (lapatinib, neratinib, osimertinib) may treat brain metastases directly. For other cancers, local treatment (SRS/surgery) is typically performed first, then systemic therapy continued. Your oncologist should assess whether your systemic therapy has CNS activity before recommending local radiation.
More from the Brain Tumour Treatment Guide
Explore related guides on brain tumour radiosurgery, particle therapy, and advanced treatment access.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Which Brain Metastasis Treatment Is Right for You?
CancerFax reviews your imaging (MRI brain with gadolinium), primary cancer pathology, and systemic disease status to identify which modality — or combination — your case calls for, and connects you with specialist centres in China, India, or internationally.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.